A synthetic racetam first developed for memory loss, then unsuccessfully tested for depression with anxiety. Its proposed action helps nerve cells take up choline, a building block of a memory-related brain messenger. Animal data in damaged brains are encouraging, but there is no solid human evidence of benefit, no long-term safety record, and it is unregulated. (Full Review)

Protocol

Common community dosing

5–35 mg/day

Some sources cite up to 80 mg/day, typically divided into two or three doses.

Dose splitting

2–3 doses/day

Short elimination half-life (about 2–3 hours) makes splitting the common approach to maintain effect across the day.

Choline pairing

Co-administer choline

Commonly co-administered with a choline source to supply substrate and reduce headache.

Time to effect

Substantive cognitive effects

Days of repeated dosing

Preclinical cognitive effects emerged only after repeated dosing over days.

Acute effects

15–60 minutes

Users report acute effects within roughly 15–60 minutes of an oral dose.

Benefits

Low: Restoration of memory and learning in cholinergic impairment

Speculative: General cognitive enhancement in healthy individuals; mood and anxiety improvement; visual and perceptual enhancement; neuroprotection

Contraindications

Pregnant or breastfeeding individuals

Children and adolescents

Significant cardiac conduction abnormalities (e.g., symptomatic bradycardia or high-grade heart block)

Anyone unable to verify product identity and purity

Key Interactions

Cholinergic drugs (acetylcholinesterase inhibitors such as donepezil, rivastigmine, galantamine)

Anticholinergic medications (over-the-counter antihistamines such as diphenhydramine, and antimuscarinics)

Choline-donor supplements (alpha-GPC, CDP-choline/citicoline)

Other racetams (piracetam, aniracetam, oxiracetam)

Psychiatric medications (antidepressants, anxiolytics)

Risk & Side Effects

Low: Headache; nausea and gastrointestinal upset; fatigue and daytime sleepiness; irritability

Speculative: Unknown long-term and chronic-use risks; tolerance; product quality and contamination hazards

Monitoring

Marker	Target	Why
ALT / AST	ALT ~10–26 U/L; AST ~10–26 U/L	Screens for liver stress from an unstudied compound
Resting heart rate	~55–70 bpm	Cholinergic activity can lower heart rate; flags excessive effect
CBC	Hemoglobin ~14–15 g/dL (men), ~13.5–14.5 g/dL (women); WBC ~3.5–6.0 ×10⁹/L	General safety screen for an unregulated product
CMP	Fasting glucose ~75–85 mg/dL; kidney filtration rate >90 mL/min/1.73m²; sodium/potassium mid-range	General organ-function and electrolyte safety screen

Cadence: Baseline, then at roughly 8–12 weeks, and periodically (every 6–12 months) during continued use.

Qualitative Assessment

Subjective memory, focus, and learning performance
Self-reported visual clarity or color vibrancy (commonly cited)
Mood and anxiety levels
Presence of side effects (headache, nausea, fatigue, irritability) as a signal to reduce dose

Coluracetam for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment